Stay updated on BMS-986036 in NASH Stage 3 Fibrosis Clinical Trial
Sign up to get notified when there's something new on the BMS-986036 in NASH Stage 3 Fibrosis Clinical Trial page.

Latest updates to the BMS-986036 in NASH Stage 3 Fibrosis Clinical Trial page
- Check2 days agoChange DetectedThe page now includes a Results section with results posted (Results First Posted 2022-09-09) and related publications. This provides access to outcomes data.SummaryDifference0.2%

- Check9 days agoNo Change Detected
- Check31 days agoChange DetectedMajor update: adds a government funding and operating status notice and marks the page as revision v3.2.0, replacing v3.1.0.SummaryDifference2%

- Check38 days agoChange DetectedAdded version tag v3.1.0 while removing several drug-safety and quality topics (Drug Safety, Counterfeit Drugs, Pharmaceutical Preparations, Substandard Drugs), indicating a narrowed content scope despite an updated version.SummaryDifference0.3%

- Check52 days agoChange DetectedRevision updated from v3.0.1 to v3.0.2. The 'Back to Top' element was removed.SummaryDifference0.1%

- Check60 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. Additionally, a 'Back to Top' feature has been added for improved navigation.SummaryDifference0.1%

- Check67 days agoChange DetectedThe web page has been updated to include new facility names and locations, as well as recent research studies related to pegbelfermin and its effects on liver diseases. Additionally, some previous location details and genetic resources have been removed.SummaryDifference6%

Stay in the know with updates to BMS-986036 in NASH Stage 3 Fibrosis Clinical Trial
Enter your email address, and we'll notify you when there's something new on the BMS-986036 in NASH Stage 3 Fibrosis Clinical Trial page.